Age 0 3 0 3 B-age
18 4 6 4 6 B-lower_bound
years 7 12 7 12 I-lower_bound

Any 0 3 13 16 O
severe 4 10 17 23 O
medical 11 18 24 31 B-chronic_disease
condition 19 28 32 41 I-chronic_disease
that 29 33 42 46 O
, 33 34 46 47 O
in 35 37 48 50 O
the 38 41 51 54 O
enrollee 42 50 55 63 O
's 50 52 63 65 O
opinion 53 60 66 73 O
, 60 61 73 74 O
is 62 64 75 77 O
likely 65 71 78 84 O
to 72 74 85 87 O
compromise 75 85 88 98 O
the 86 89 99 102 O
participant 90 101 103 114 O
's 101 103 114 116 O
ability 104 111 117 124 O
to 112 114 125 127 O
complete 115 123 128 136 O
the 124 127 137 140 O
trial 128 133 141 146 O

Ascites 0 7 147 154 B-chronic_disease

Bilirubin 0 9 155 164 B-clinical_variable
2 10 11 165 166 B-lower_bound
mg 12 14 167 169 I-lower_bound
/ 14 15 169 170 I-lower_bound
dL 15 17 170 172 I-lower_bound

Current 0 7 173 180 O
use 8 11 181 184 O
of 12 14 185 187 O
azathioprine 15 27 188 200 B-treatment
, 27 28 200 201 O
mercaptopurine 29 43 202 216 B-treatment
, 43 44 216 217 O
didanosine 45 55 218 228 B-treatment
, 55 56 228 229 O
cyclophosphamide 57 73 230 246 B-treatment
, 73 74 246 247 O
or 75 77 248 250 O
probenecid 78 88 251 261 B-treatment

Encephalopathy 0 14 262 276 B-chronic_disease

History 0 7 277 284 O
of 8 10 285 287 O
gout 11 15 288 292 B-chronic_disease
- 16 17 293 294 O
crystal 18 25 295 302 O
proven 26 32 303 309 O
or 33 35 310 312 O
historical 36 46 313 323 O
as 47 49 324 326 O
defined 50 57 327 334 O
by 58 60 335 337 O
ACR 61 64 338 341 O
criteria 65 73 342 350 O
listed 74 80 351 357 O
above 81 86 358 363 O

INR 0 3 364 367 O
1.7 4 7 368 371 O
, 7 8 371 372 O
not 9 12 373 376 O
on 13 15 377 379 O
Warfarin 16 24 380 388 B-treatment
therapy 25 32 389 396 I-treatment

Patients 0 8 397 405 O
who 9 12 406 409 O
are 13 16 410 413 O
not 17 20 414 417 O
candidates 21 31 418 428 O
for 32 35 429 432 O
any 36 39 433 436 O
of 40 42 437 439 O
the 43 46 440 443 O
recommended 47 58 444 455 O
prophylactic 59 71 456 468 B-treatment
medications 72 83 469 480 I-treatment
( 84 85 481 482 O
colchicine 85 95 482 492 B-treatment
, 95 96 492 493 O
naprosyn 97 105 494 502 B-treatment
or 106 108 503 505 O
glucocorticoids 109 124 506 521 B-treatment
) 124 125 521 522 O

Patients 0 8 523 531 O
with 9 13 532 536 O
a 14 15 537 538 O
history 16 23 539 546 O
of 24 26 547 549 O
prior 27 32 550 555 O
solid 33 38 556 561 B-treatment
organ 39 44 562 567 I-treatment
/ 45 46 568 569 I-treatment
hematopoietic 47 60 570 583 I-treatment
transplantation 61 76 584 599 I-treatment

Patients 0 8 600 608 O
with 9 13 609 613 O
chronic 14 21 614 621 B-chronic_disease
liver 22 27 622 627 I-chronic_disease
disease 28 35 628 635 I-chronic_disease

Patients 0 8 636 644 O
with 9 13 645 649 O
malignancies 14 26 650 662 B-cancer
that 27 31 663 667 O
are 32 35 668 671 O
currently 36 45 672 681 O
active 46 52 682 688 O

Patients 0 8 689 697 O
with 9 13 698 702 O
myelodysplasia 14 28 703 717 B-clinical_variable
and 29 32 718 721 O
hemoglobin 33 43 722 732 B-clinical_variable
of 44 46 733 735 O
< 47 48 736 737 O
8.5 49 52 738 741 B-upper_bound
g 53 54 742 743 I-upper_bound
/ 54 55 743 744 I-upper_bound
dL 55 57 744 746 I-upper_bound

Patients 0 8 747 755 O
with 9 13 756 760 O
serum 14 19 761 766 B-clinical_variable
uric 20 24 767 771 I-clinical_variable
acid 25 29 772 776 I-clinical_variable
levels 30 36 777 783 I-clinical_variable
> 37 38 784 785 O
15 38 40 785 787 B-lower_bound
mg 41 43 788 790 I-lower_bound
/ 43 44 790 791 I-lower_bound
dl 44 46 791 793 I-lower_bound

Previous 0 8 794 802 O
allergy 9 16 803 810 O
or 17 19 811 813 O
intolerance 20 31 814 825 O
to 32 34 826 828 O
allopurinol 35 46 829 840 B-allergy_name
or 47 49 841 843 O
febuxostat 50 60 844 854 B-allergy_name

Previous 0 8 855 863 O
history 9 16 864 871 O
of 17 19 872 874 O
failure 20 27 875 882 O
to 28 30 883 885 O
reach 31 36 886 891 O
target 37 43 892 898 O
uric 44 48 899 903 O
acid 49 53 904 908 O
levels 54 60 909 915 O
despite 61 68 916 923 O
therapy 69 76 924 931 B-treatment
with 77 81 932 936 I-treatment
allopurinol 82 93 937 948 I-treatment
at 94 96 949 951 O
dose 97 101 952 956 O
> 102 103 957 958 O
300 104 107 959 962 B-lower_bound
mg 108 110 963 965 I-lower_bound
/ 110 111 965 966 I-lower_bound
day 111 114 966 969 I-lower_bound

Prior 0 5 970 975 O
febuxostat 6 16 976 986 B-treatment
use 17 20 987 990 O

Serum 0 5 991 996 B-clinical_variable
albumin 6 13 997 1004 I-clinical_variable
< 14 15 1005 1006 O
3.5 15 18 1006 1009 B-upper_bound
g 19 20 1010 1011 I-upper_bound
/ 20 21 1011 1012 I-upper_bound
dL 21 23 1012 1014 I-upper_bound

Serum 0 5 1015 1020 B-clinical_variable
urate 6 11 1021 1026 I-clinical_variable
level 12 17 1027 1032 I-clinical_variable
6.8 18 21 1033 1036 O
mg 22 24 1037 1039 O
/ 24 25 1039 1040 O
dl 25 27 1040 1042 O

Stage 0 5 1043 1048 B-chronic_disease
4 6 7 1049 1050 I-chronic_disease
or 8 10 1051 1053 I-chronic_disease
5 11 12 1054 1055 I-chronic_disease
Chronic 13 20 1056 1063 I-chronic_disease
Kidney 21 27 1064 1070 I-chronic_disease
Disease 28 35 1071 1078 I-chronic_disease
( 36 37 1079 1080 I-chronic_disease
CKD 37 40 1080 1083 I-chronic_disease
) 40 41 1083 1084 I-chronic_disease
- 42 43 1085 1086 O
defined 44 51 1087 1094 O
as 52 54 1095 1097 O
eGFR 55 59 1098 1102 B-clinical_variable
of 60 62 1103 1105 O
< 63 64 1106 1107 O
30 64 66 1107 1109 B-upper_bound
ml 67 69 1110 1112 I-upper_bound
/ 69 70 1112 1113 I-upper_bound
min 70 73 1113 1116 I-upper_bound

Women 0 5 1117 1122 B-gender

less 0 4 1123 1127 O
than 5 9 1128 1132 O
50 10 12 1133 1135 B-upper_bound
years 13 18 1136 1141 I-upper_bound
of 19 21 1142 1144 O
age 22 25 1145 1148 B-age

non 0 3 1149 1152 B-cancer
- 3 4 1152 1153 I-cancer
melanoma 4 12 1153 1161 I-cancer
skin 13 17 1162 1166 I-cancer
cancer 18 24 1167 1173 I-cancer

